相关实验视频
Updated: May 16, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
在连续葡萄糖指标中对低血糖治疗的计算
Elliott C Pryor1, Anas El Fathi1, Marc D Breton1
1Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.
Journal of diabetes science and technology
|April 5, 2025
概括
持续血糖监测 (CGM) 数据可以通过计算低血糖治疗 (HTs) 来改进. 新方法准确量化避免的低血糖症,改善糖尿病管理和治疗适应,以更好地控制血糖.
科学领域:
- 生物医学工程 生物医学工程
- 在医疗保健中的数据科学.
- 内分泌学 在内分泌学.
背景情况:
- 持续血糖监测 (CGM) 提供了宝贵的糖尿病数据,但忽略了诸如低血糖治疗 (HTs) 等行为因素.
- 低血糖治疗掩盖了实际的葡萄糖暴露,可能导致管理错误.
- 对低血糖的准确评估需要将行为数据与CGM指标整合起来.
研究的目的:
- 开发一种将HT纳入基于CGM的指标的方法.
- 为了规范低血糖暴露的量化,考虑到治疗的积极性和严重性.
- 引入一个HT检测器,用于识别CGM数据中的未经记录的HT.
主要方法:
- 提出了一种新的方法,将HT整合到CGM指标中,用于标准化的低血糖量化.
- 开发了一种HT检测器,用于识别CGM数据中的治疗实例.
- 将HT修饰的低血糖指标应用于运行到运行的治疗适应系统.
主要成果:
- 使用in-silico数据,重建了高准确度的避免低血糖暴露 (R2 = .94).
- 在临床数据上,HT检测器的F1得分为0.72.
- 在运行到运行系统中,平均每日HTs从3.3降至1.6,同时保持84%的范围时间.
结论:
- 新的指标将HT行为整合到CGM分析中,用于行为敏感低血糖评估.
- 这种方法通过提供更强大的治疗见解来增强1型糖尿病 (T1D) 的管理.
- 对于改善糖尿病护理,HT变异性可以无地纳入现有的CGM方法.
相关概念视频
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Diabetes: Management and Pharmacotherapy
214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
SBAR II: Application of SBAR
4.2K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.2K
Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
128
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
128

